Skip to main content
Mia Levy, MD, Oncology, Chicago, IL, Rush University Medical Center

MiaALevyMDPhD

Oncology Chicago, IL

Breast Cancer

Director, Rush University Cancer Center

Dr. Levy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Levy's full profile

Already have an account?

  • Office

    1725 W. Harrison St., ∙ Chicago, IL 60612
    Suite 82
    Chicago, IL 60612
    Phone+1 312-942-4624
    Fax+1 312-942-3192
  • Is this information wrong?

Education & Training

  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2003 - 2005
  • Rush Medical College of Rush University Medical Center
    Rush Medical College of Rush University Medical CenterClass of 2003

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2004 - Present
  • IL State Medical License
    IL State Medical License 2020 - 2026
  • TN State Medical License
    TN State Medical License 2009 - 2021
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Journal Articles

  • Clinical Application of Computational Methods in Precision Oncology  
    Mia A Levy, Christopher R Cogle, JAMA Oncology
  • Qualitative Study of System-Level Factors Related to Genomic Implementation  
    Geoffrey S Ginsburg, Joshua C Denny, Carol R Horowitz, Mia A Levy, Barbara A Bernhardt, Paul R Dexter, Stephen E Kimmel, Lori A Orlando, Nature

Authored Content

  • Clinical Application of Computational Methods in Precision OncologyMay 2020
  • Clinical Application of Computational Methods in Precision OncologyMay 2020

Press Mentions

  • Foundation Medicine and Its Collaborators Announce Acceptance of 21 Abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
    Foundation Medicine and Its Collaborators Announce Acceptance of 21 Abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingMay 26th, 2023
  • FDA Approves FoundationOne Liquid CDx as Companion Diagnostic for Exkivity
    FDA Approves FoundationOne Liquid CDx as Companion Diagnostic for ExkivityMay 5th, 2023
  • FoundationOne®Liquid CDx Receives FDA-Approval as a Companion Diagnostic for EXKIVITY® (Mobocertinib) to Identify Patients with EGFR Exon 20 Insertion Mutations in Advanced Non-Small Cell Lung Cancer
    FoundationOne®Liquid CDx Receives FDA-Approval as a Companion Diagnostic for EXKIVITY® (Mobocertinib) to Identify Patients with EGFR Exon 20 Insertion Mutations in Advanced Non-Small Cell Lung CancerMay 4th, 2023
  • Join now to see all

Hospital Affiliations